Excelsior Correspondent
JAMMU, Jan 18: Patanjali Research Foundation (PRF) has decided to start their research on the spike protein of Omicron’s latest JN-1 variant.
The decision in this regard was announced by Acharya Balkrishna , General Secretary , PRF in a function held here today.
Acharya Balkrishna said that this is the first time a study on spike protein of Covid’s JN-1 variant is happening in India.
He said that he is proud that Patanjali Research Foundation is the first organisation in the country which is conducting a detailed research on the JN-1 variant.
He further stated that Patanjali will show the world how it conducts research on Ayurvedic medicines in line with the standards of modern science.
The spike protein of JN-1 COVID varient has been brought to Patanjali Research Foundation from China’s Sino Biological Lab.
The World Health Organisation (WHO) has classified the SARS-CoV-2 sub-variant JN-1 as a separate variant of interest (VOI) from its parent lineage BA.2.86.
JN-1 variant is a sub-variant of the SARS-CoV-2, the virus which caused the deadly pandemic.
Patanjali Research Foundation’s chief scientist Dr Anurag Varshney said that they will test the effect of Coronil, Patanjali’s potential anti-Covid drug, on the spike protein JN-1 variant.
Follow our WhatsApp channel
